drug_type
RELEVANT_DRUG
intervention_type
Monoclonal antibody (biologic drug)
drug_description
Humanized anti-HER2 monoclonal antibody (trastuzumab-like) that binds the HER2 extracellular domain, inhibits HER2 signaling, and mediates antibody-dependent cellular cytotoxicity (ADCC).
nci_thesaurus_concept_id
C179282
nci_thesaurus_definition
An Fc-engineered monoclonal antibody targeting the tyrosine kinase receptor epidermal growth factor receptor 2 (HER2; ErbB2), with potential immunomodulating and antineoplastic activities. Upon administration, inetetamab targets and specifically binds to HER2 on tumor cells, thereby blocking HER2-mediated signaling. This may inhibit proliferation of HER2-expressing tumor cells. In addition, the Fab region of inetetamab may induce antibody-dependent cell-mediated cytotoxicity (ADCC) against tumor cells that overexpress HER2. HER2 is overexpressed in a variety of cancer cell types and is associated with increased tumor cell proliferation.
drug_mesh_term
Antibodies, Monoclonal, Humanized
drug_category
INHIBITORY ANTIBODY
drug_class
Inhibitor
drug_delivery_route
Intravenous
drug_mechanism_of_action
Humanized anti-HER2 monoclonal antibody that binds the HER2 extracellular domain, blocks HER2 receptor activation and dimerization to inhibit downstream signaling and tumor cell proliferation, and recruits immune effector cells to mediate antibody-dependent cellular cytotoxicity (ADCC).
drug_name
Inetetamab
nct_id_drug_ref
NCT05980208